Navigation Links
Intrinsic Therapeutics Announces CE Mark for Barricaid Anular Prosthesis
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- Intrinsic Therapeutics, Inc. announced today that it has received a CE mark for its Barricaid(R) anular prosthesis for use in reconstructing soft tissues of the spine. The CE mark gives Intrinsic approval to distribute the Barricaid throughout the European Union and in other countries that recognize the CE mark.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090414/NE98588LOGO )

"We are very pleased with receiving the CE mark and believe that this event reflects, in part, on the very positive clinical results in our current, prospective clinical study of the Barricaid anular prosthesis," stated Barry Sands, Vice President Regulatory, Clinical, and Quality Affairs. The Barricaid (www.in-thera.com) is a revolutionary partial disc prosthesis that enables surgeons to directly reconstruct the anulus of the intervertebral disc in patients with lumbar disc herniations and sciatica as part of a standard, minimal access discectomy procedure. More than 500,000 discectomies are performed worldwide each year.

"This approval gives Intrinsic the opportunity to offer surgeons, patients, and payers the potential for a truly better outcome in the treatment of lumbar disc herniation, the most common degenerative condition of the spine," stated Greg Lambrecht, President & CEO. "The Barricaid and its approval in the European Union is the culmination of years of extensive pre-clinical and clinical development to address this fundamental, unmet need in spine surgery. Surgeons have tried many different techniques over the years to repair the anulus including sutures, glues, and clips with very limited success. The Barricaid offers a new surgical strategy by reconstructing the anulus and anchoring it to the vertebral body for a more secure solution. Intrinsic and the surgeons we serve are very excited by the positive results from the initial clinical study of the Barricaid that helped us reach this important milestone."

About Intrinsic Therapeutics

Intrinsic Therapeutics is dedicated to treating soft-tissue injuries of the spine. Intrinsic's Barricaid anular reconstructive products are used during discectomy to definitively close defects in the posterior anulus. By restoring anular competence, the Barricaid family of products may reduce the risk of recurrent herniation while maintaining disc height and biomechanics.

    Contacts:
    Scott LeBlanc                               Tom Guest
    Director Finance                            VP Sales & Marketing
    Intrinsic Therapeutics, Inc.                Intrinsic Therapeutics, Inc.
    781-932-0222 ext. 173                       781-932-0222 ext. 133
    finance@in-thera.com


'/>"/>
SOURCE Intrinsic Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: